Evvy raises $40M as it seeks to further women's health research with vaginal microbiome data

Key Points:

• Evvy, a women’s health company founded in 2021, raised $40 million in a Series B funding round led by Catalio Capital Management to expand its at-home vaginal microbiome testing and personalized care platform.
• The company offers the world’s only at-home CLIA-certified and CLEP-certified metagenomic next-generation sequencing (mNGS) test, analyzing vaginal microbes from a single swab mailed to their lab, with results reviewed by clinicians and delivered via a patient portal.
• Evvy serves over 100,000 patients and 3,000 practitioners in the U.S., has published 15 peer-reviewed studies, and aims to build a large dataset linking microbiome biology to symptoms and health outcomes to improve precision medicine for women.
• The startup launched EvvyAI, an AI assistant providing real-time vaginal health guidance based on microbiome data, and is expanding into fertility research by studying connections between vaginal microbiomes and infertility, IVF success, and pregnancy complications.
• CEO Priyanka Jain envisions Evvy eventually creating a new-age, at-home Pap smear offering comprehensive, non-invasive insights into women’s reproductive health conditions, emphasizing the need for better data and patient involvement to advance women’s health care.